Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$5.35
+3.5%
$6.40
$2.78
$8.85
$29.05M1.0329,320 shs9,079 shs
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
$0.68
$4.18
$0.67
$90.20
$292K4.89220,565 shs367,850 shs
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
$1.60
-30.4%
$2.31
$1.41
$13.20
$2.11M0.54176,310 shs3.47 million shs
Yumanity Therapeutics, Inc. stock logo
YMTX
Yumanity Therapeutics
$0.62
-7.5%
$0.98
$0.95
$13.23
$6.73M0.32473,083 shs172,767 shs
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
+5.52%-8.39%-9.63%+2.88%+40.05%
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-0.38%-11.69%-83.04%-89.85%-99.19%
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
-29.82%-13.51%-17.95%-24.53%-82.25%
Yumanity Therapeutics, Inc. stock logo
YMTX
Yumanity Therapeutics
0.00%+27.55%+11.57%-76.78%-84.42%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
2.8367 of 5 stars
3.55.00.00.00.03.30.6
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
0.372 of 5 stars
0.02.00.00.03.20.01.3
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
1.0129 of 5 stars
3.33.00.00.00.60.00.6
Yumanity Therapeutics, Inc. stock logo
YMTX
Yumanity Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
3.00
Buy$15.50189.72% Upside
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
3.00
BuyN/AN/A
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
2.50
Moderate Buy$21.001,212.50% Upside
Yumanity Therapeutics, Inc. stock logo
YMTX
Yumanity Therapeutics
N/AN/AN/AN/A

Current Analyst Ratings

Latest CYCC, APVO, YMTX, and APRE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/27/2024
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$9.00 ➝ $11.00
3/26/2024
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$580K50.09N/AN/A$4.54 per share1.18
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
$3.11M0.09N/AN/A$28.58 per share0.02
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
$420K5.03N/AN/A$0.57 per share2.81
Yumanity Therapeutics, Inc. stock logo
YMTX
Yumanity Therapeutics
$4.84M1.39N/AN/A$2.28 per share0.27

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$14.29M-$3.99N/AN/AN/AN/A-65.58%-52.37%5/20/2024 (Estimated)
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-$17.41MN/A0.00N/AN/AN/A-112.27%-64.39%5/9/2024 (Estimated)
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
-$22.56M-$27.22N/AN/AN/AN/A-448.19%-151.29%5/9/2024 (Estimated)
Yumanity Therapeutics, Inc. stock logo
YMTX
Yumanity Therapeutics
-$39.50M-$3.00N/AN/A-660.61%-263.34%-107.08%N/A

Latest CYCC, APVO, YMTX, and APRE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/26/2024Q4 2023
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$0.56-$0.92-$0.36-$0.92$0.33 million$0.01 million
3/19/2024Q4 2023
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
-$6.35-$6.23+$0.12-$6.23N/A$0.03 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/AN/AN/AN/AN/A
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
N/AN/AN/AN/AN/A
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
N/AN/AN/AN/AN/A
Yumanity Therapeutics, Inc. stock logo
YMTX
Yumanity Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/A
5.13
5.13
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
N/A
2.64
2.64
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
N/A
0.91
0.91
Yumanity Therapeutics, Inc. stock logo
YMTX
Yumanity Therapeutics
N/A
2.21
2.21

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
34.19%
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
8.06%
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
23.58%
Yumanity Therapeutics, Inc. stock logo
YMTX
Yumanity Therapeutics
25.10%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
75.43 million4.30 millionNo Data
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
40428,000420,000Not Optionable
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
2,0181.32 million1.21 millionOptionable
Yumanity Therapeutics, Inc. stock logo
YMTX
Yumanity Therapeutics
4010.86 million9.50 millionNot Optionable

CYCC, APVO, YMTX, and APRE Headlines

SourceHeadline
Yumanity Therapeutics (NASDAQ:YMTX) Stock Price Up 20.5%Yumanity Therapeutics (NASDAQ:YMTX) Stock Price Up 20.5%
americanbankingnews.com - April 24 at 2:18 AM
JSPR Jasper Therapeutics, Inc.JSPR Jasper Therapeutics, Inc.
seekingalpha.com - March 20 at 7:11 PM
Cara Therapeutics Inc CARACara Therapeutics Inc CARA
morningstar.com - November 3 at 7:42 AM
Yumanity Therapeutics Inc.Yumanity Therapeutics Inc.
thestreet.com - October 6 at 6:24 PM
Former Onyx CEO Returns to Biotech to Launch Boston Start UpFormer Onyx CEO Returns to Biotech to Launch Boston Start Up
thestreet.com - July 5 at 1:02 AM
Kineta raises $6M through registered direct offeringKineta raises $6M through registered direct offering
bizjournals.com - May 1 at 1:51 AM
Colorectal Cancer Therapeutics Market Size to Surpass US$ 24.58 Billion by 2030 - Growth Plus ReportsColorectal Cancer Therapeutics Market Size to Surpass US$ 24.58 Billion by 2030 - Growth Plus Reports
finance.yahoo.com - February 22 at 10:00 AM
Yumanity Therapeuticss Return On Capital Employed InsightsYumanity Therapeutics's Return On Capital Employed Insights
msn.com - December 26 at 1:21 PM
Kineta finalizes reverse merger with Yumanity, secures additional fundingKineta finalizes reverse merger with Yumanity, secures additional funding
bizjournals.com - December 20 at 6:58 PM
Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to ...Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to ...
bakersfield.com - December 5 at 6:26 PM
Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with KinetaYumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta
finance.yahoo.com - December 5 at 6:26 PM
Why Is Yumanity Therapeutics (YMTX) Stock Up Today?Why Is Yumanity Therapeutics (YMTX) Stock Up Today?
investorplace.com - December 5 at 3:03 PM
Yumanity Therapeutics Inc: Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate DevelopmentsYumanity Therapeutics Inc: Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
finanznachrichten.de - November 14 at 11:42 AM
Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate DevelopmentsYumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
finance.yahoo.com - November 14 at 11:42 AM
Yumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.Yumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.
finance.yahoo.com - November 10 at 4:45 PM
Yumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with KinetaYumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta
finance.yahoo.com - August 29 at 10:16 AM
Yumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate DevelopmentsYumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
finance.yahoo.com - August 4 at 6:52 PM
Glioblastoma Pipeline Analysis: Key Pharma Players Set to Develop Novel Therapies and Explore Countless OpportunitiesGlioblastoma Pipeline Analysis: Key Pharma Players Set to Develop Novel Therapies and Explore Countless Opportunities
medgadget.com - July 14 at 1:51 AM
YUMANITY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of…YUMANITY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of…
lawyer-monthly.com - July 5 at 10:55 PM
Inside Kinetas plans after unveiling reverse merger dealInside Kineta's plans after unveiling reverse merger deal
finance.yahoo.com - June 8 at 9:39 PM
Seattle biotech Kineta to go public in merger deal with Yumanity TherapeuticsSeattle biotech Kineta to go public in merger deal with Yumanity Therapeutics
bizjournals.com - June 7 at 11:47 PM
Short Volatility Alert: Yumanity Therapeutics, Inc.Short Volatility Alert: Yumanity Therapeutics, Inc.
msn.com - June 7 at 6:47 PM
Yumanity leaps as it reveals Janssen asset purchase and merger deal with KinetaYumanity leaps as it reveals Janssen asset purchase and merger deal with Kineta
thepharmaletter.com - June 6 at 5:23 PM
Yumanity to Sell Neurosciences Candidates, Merge With Kineta >YMTXYumanity to Sell Neurosciences Candidates, Merge With Kineta >YMTX
marketwatch.com - June 6 at 12:23 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aprea Therapeutics logo

Aprea Therapeutics

NASDAQ:APRE
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Aptevo Therapeutics logo

Aptevo Therapeutics

NASDAQ:APVO
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Cyclacel Pharmaceuticals logo

Cyclacel Pharmaceuticals

NASDAQ:CYCC
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
Yumanity Therapeutics logo

Yumanity Therapeutics

NASDAQ:YMTX
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.